TY - JOUR
T1 - Systemic sclerosis
T2 - Current concepts of skin and systemic manifestations
AU - Pearson, David R.
AU - Werth, Victoria P.
AU - Pappas-Taffer, Lisa
N1 - Publisher Copyright:
© 2018
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Systemic sclerosis is an uncommon autoimmune connective tissue disease with multiorgan system involvement and significant associated morbidity and mortality. Cutaneous signs and clinical manifestations are of particular importance, as they may be recognized before systemic manifestations, allowing earlier risk stratification into the limited and diffuse cutaneous subtypes, as well as earlier initiation of treatment. Important cutaneous manifestations include Raynaud's phenomenon, digital ulcers, cutaneous sclerosis, calcinosis cutis, telangiectasias, pruritus, and dyspigmentation. Despite investigation of a wide variety of treatments, no FDA-approved pharmacologic therapies exist for systemic sclerosis, and data from high-quality studies are limited. In the following review, we will discuss skin-directed therapies. Although there is evidence to support specific treatments for Raynaud's phenomenon, digital ulcers, and cutaneous sclerosis, there are limited rigorous studies evaluating the treatment of other cutaneous signs and clinical manifestations. Additional randomized-controlled trials and large observational studies are necessary to develop future evidence-based treatment options.
AB - Systemic sclerosis is an uncommon autoimmune connective tissue disease with multiorgan system involvement and significant associated morbidity and mortality. Cutaneous signs and clinical manifestations are of particular importance, as they may be recognized before systemic manifestations, allowing earlier risk stratification into the limited and diffuse cutaneous subtypes, as well as earlier initiation of treatment. Important cutaneous manifestations include Raynaud's phenomenon, digital ulcers, cutaneous sclerosis, calcinosis cutis, telangiectasias, pruritus, and dyspigmentation. Despite investigation of a wide variety of treatments, no FDA-approved pharmacologic therapies exist for systemic sclerosis, and data from high-quality studies are limited. In the following review, we will discuss skin-directed therapies. Although there is evidence to support specific treatments for Raynaud's phenomenon, digital ulcers, and cutaneous sclerosis, there are limited rigorous studies evaluating the treatment of other cutaneous signs and clinical manifestations. Additional randomized-controlled trials and large observational studies are necessary to develop future evidence-based treatment options.
UR - http://www.scopus.com/inward/record.url?scp=85049465133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049465133&partnerID=8YFLogxK
U2 - 10.1016/j.clindermatol.2018.04.004
DO - 10.1016/j.clindermatol.2018.04.004
M3 - Article
C2 - 30047430
AN - SCOPUS:85049465133
SN - 0738-081X
VL - 36
SP - 459
EP - 474
JO - Clinics in Dermatology
JF - Clinics in Dermatology
IS - 4
ER -